A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients

International Journal of Clinical Practice, Supplement

Volumn , Issue 145, 2004, Pages 16-22

  Ding, Phillip Yu An ^a   Chu, K M ^b   Chiang, H T ^c   Shu, K H ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptor blockers; Antihypertensives; Hypertension; Losartan; Telmisartan

Indexed keywords

LOSARTAN; PLACEBO; TELMISARTAN;

ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VISCOSITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HEMOSTASIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; SIDE EFFECT; TAIWAN;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 10344248150     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14: 83-90.
2. Cutler JA. High blood pressure and end-organ damage. J Hypertens 1996; 14 (Suppl.): S3-S6.
3. World Health Organization Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
4. Mancia G, Cattaneo BM, Omboni S, et al. Clinical benefits of a consistent reduction in blood pressure. J Hypertens 1998; 16 (Suppl.): S35-S39.
5. Tseng WP. Epidemiology of hypertension among Chinese in Taiwan. J Hum Hypertens 1990; 4: 144-6.
6. Lien WP, Lai LP, Chen JJ, et al. A retrospective hospital-based study of coronary risk factors in Taiwan. Analysis of patients with established diagnoses. Jpn Heart J 1998; 39: 435-44.
7. Gao M, Ikeda K, Hattori H, et al. Cardiovascular risk factors emerging in Chinese populations undergoing urbanization. Hypertens Res 1999; 22: 209-15.
8. Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000; 14: 749-63.
9. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995; 25: 305-13.
10. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-22.
11. Pickering T, for an American Society of Hypertension Ad Hoc Panel. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996; 9: 1-11.
12. White W. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 (Suppl. 6): S9-S15.
13. Tsementzis SA, Gill JS, Hitchcock ER, et al. Diurnal variation of and activity during the onset of stroke. Neurosurgery 1985; 17: 901-4.
14. White WB. Relevance of the trough-to-peak ratio to the 24 h blood pressure load. Am J Hypertens 1996; 10 (Suppl. 2): 91S, 108A-96S, 109S.
15. Smith DHG. Treatment of hypertension with an angiotensin II receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002; 24: 1484-501.
16. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
17. Nakashima M, Umemura K. The clinical pharmacology of losartan in Japanese subjects and patients. Blood Press 1996; 2 (Suppl.): 62-6.
18. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
19. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-17.
20. Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-7.
21. Lu Y-H, Hwang Y-S. Losartan monotherapy in systemic hypertension - an open-label, uncontrolled trial. Acta Cardiol Sin 2002; 18: 167-72.
22. Mallion JM, Siché JP, Lacourcière Y, et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-64.
23. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
24. Zanchetti A, Hansson L, Menard J, et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19: 819-25.
25. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-6.
26. Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131-8.
27. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-56.
28. Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-67.
29. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 (Suppl. 1): 6-11.
30. 14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-22.
31. Stangier J, Su CAPF, van Heiningen PNM, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001; 38: 672-85.